Alzheimer’s setback makes Elan takeover bait to Biogen – Worcester Telegram

July 28, 2012 by  
Filed under Alzheimers News

Sponsored By
Alzheimer's setback makes Elan takeover bait to Biogen
Worcester Telegram
Elan sank 15 percent, the most since 2009, on July 24 after disappointing results for bapineuzumab, an Alzheimer's therapy developed with Pfizer Inc. and Johnson & Johnson. The failure of that drug would leave Elan with a single major product, the
Analysts: Ailing Elan casts buyout bait for Biogen IdecFierceBiotech
Analysts see sale of Elan to Biogen Idec as likelyFiercePharma

all 8 news articles »

More Info: Click here

Speak Your Mind

Tell us what you're thinking...
and oh, if you want a pic to show with your comment, go get a gravatar!

*